Interim Report January – June 2007 Tripep AB (publ)

• Research and development costs amounted to SEK 7.7 million
• The loss after tax was SEK 13.8 million
• Earnings per share were SEK 0.29
• The company had no net sales for the period
• The company has received patent protection for administration of ChronVac-C® vaccine using electroporation

Events after the end of the reporting period
• After the end of the reporting period, Tripep received final approval to start a clinical study of ChronVac-C® on patients with a chronic infection of the Hepatitis C virus. The study is scheduled to start in September/October 2007.



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se